Media.Player

Diagnosis of osteoarthritis

Summary

First serum biomarker test based on thrombospondin-4 autoantibodies that helps to support the clinical diagnosis of osteoarthritis.

Technology Benefits

First biomarker of osteoarthritis

Technology Application

The first serum biomarker test that helps to support the clinical diagnosis of osteoarthritis and furthermore may provide a tool that allows the monitoring of therapeutic success of drug candidates for the treatment of arthrosis.

Detailed Technology Description

Autoantibodies against the cartilage protein thrombospondin 4 (TSP-4) occur in the course of arthrosis. Rheumatoid arthritis is characterized by the presence of autoantibodies, but autoantibodies against TSP-4 have jet not been described for arthrosis. In addition to TSP-4, the researchers have found autoantibodies against the cartilage oligomeric matrix protein (COMP) and the C-type lectin domain family 3 member A (CLEC3A) in the course of OA, which may be used in a combined test together with TSP-4 in order to strengthen significance of diagnosis

Type of Cooperation

Licensing

Application Date

12/12/2018 00:00:00

Application No.

WO2018EP84451 20181212

Classes

- international:
G01N33/564
- cooperative:
G01N33/564; G01N2800/105

Others

Patent application

ID No.

4812

Country/Region

Germany